Icecure Medical Ltd (ICCM)
IceCure Medical Ltd is a commercial-stage medical device company listed on NASDAQ under the ticker ICCM. The company focuses on the research, development, and marketing of cryoablation systems, disposables, and related technologies used in tumor treatment across the United States, Japan, India, China, Israel, and other international markets. Its portfolio includes the ProSense single-probe cryoablation system for malignant breast tumors, associated consumables such as CryoProbes needles and guiding needles/introducers, and the IceSense3 system for applications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. IceCure is also developing the XSense single-probe system and the MSense multi-probe system. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics. Incorporated in 2006, IceCure Medical is headquartered in Caesarea, Israel.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ICCM
|
$5.36
|
59.4% Upside
|
Bargain
|
$30.50
|
806.4% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-0.7x
|
1.4x
|
3.3x
|
11.41 M
|
3.636 M
|
1.2%
|
64.1%
|
-29.8
|
—
|
94.6%
|
